Arbor Biotechnologies, a biotechnology company discovering and developing the next generation of genetic medicines, announced the closing of a $73.9 million Series C financing to support the advancement of its pipeline of novel gene editing therapeutics targeting diseases in the liver and central nervous system.

ARCH Venture Partners and TCGX led the financing, with participation from new investors QIA, Partners Investment, Revelation Partners, and Kerna Ventures and existing investors, including funds managed by abrdn Inc., Ally Bridge Group, Arrowmark Partners, Deep Track Capital, Piper Heartland Healthcare Capital, Surveyor Capital, Temasek, T. Rowe Price Associates and Vertex Pharmaceuticals Incorporated.